ReviewCancers2022
Biomarkers for the Detection and Risk Stratification of Aggressive Prostate Cancer.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Liquid biopsy in the clinical management of tumor of urinary system: current status and future developments.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Integrative Whole-Genome and Epigenome Profiling of cfDNA in Familial Prostate Cancer: Insights from a Pilot Study.Biomedicines · 2026Article
- Machine Learning Approach Identifies miRNA Biomarkers for Post Surgical Patient Stratification in Prostate Cancer.The Prostate · 2025Article
- Metabolomics-Based Liquid Biopsy for Predicting Clinically Significant Prostate Cancer.Cancers · 2025Review
- Applications and prospects of spatial transcriptomics in prostate cancer research: A narrative review.Current urology · 2025Article
- Identification of protein-coding genes associated with metastatic prostate cancer.Endocrine-related cancer · 2025Article
- Role of circulating MicroRNAs in prostate cancer diagnosis and risk stratification in the MCC Spain study.Scientific reports · 2025Article
- Integrative analysis of blood biomarkers and clinical variables improves early detection of aggressive prostate cancer.Scientific reports · 2025Article
- Transcriptional profiles of circulating tumor cells reflect heterogeneity and treatment resistance in advanced prostate cancer.Journal of experimental & clinical cancer research : CR · 2025Article
- Digital spatial profiling identifies phospho-JNK as a biomarker for early risk stratification of aggressive prostate cancer.Frontiers in oncology · 2025Article
- Blood Extracellular Vesicles Beyond Circulating Tumour Cells: A Valuable Risk Stratification Biomarker in High-Risk Non-Muscle-Invasive Bladder Cancer Patients.Biomedicines · 2024Article
- A Blood-Based Immune Gene Signature with Prognostic Significance in Localized Prostate Cancer.Cancers · 2023Article
- Detection Rate of Prostate Cancer in Repeat Biopsy after an Initial Negative Magnetic Resonance Imaging/Ultrasound-Guided Biopsy.Diagnostics (Basel, Switzerland) · 2023Article
- Advancements in Biomarkers of Prostate Cancer: A Review.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current strategies for the clinical management of prostate cancer are inadequate for a precise risk stratification between indolent and aggressive tumors. Recently developed tissue-based molecular biomarkers have refined the risk assessment of the disease. The characterization of tissue biopsy components and subsequent identification of relevant tissue-based molecular alterations have the potential to improve the clinical decision making and patient outcomes. However, tissue biopsies are invasive and spatially restricted due to tumor heterogeneity. Therefore, there is an urgent need for complementary diagnostic and prognostic options. Liquid biopsy approaches are minimally invasive with potential utility for the early detection, risk stratification, and monitoring of tumors. In this review, we focus on tissue and liquid biopsy biomarkers for early diagnosis and risk stratification of prostate cancer, including modifications on the genomic, epigenomic, transcriptomic, and proteomic levels. High-risk molecular alterations combined with orthogonal clinical parameters can improve the identification of aggressive tumors and increase patient survival.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.